FDA gives nod of approval to first derived mesenchymal stromal cell therapy for the treatment of pediatric patients with ...

From detecting early disease to guiding treatment plans, clinicians are finding ctDNA testing increasingly important.

Ensartinib has received FDA approval for the first-line treatment of ALK-positive locally advanced or metastatic non–small ...

Pharmacologic strategies may be able to prevent abnormal uterine bleeding in patients undergoing stem cell transplant.

This past year, the role of ctDNA testing has expanded to guide treatment decisions for providers and patients with cancer.

According to real-world data, no survival advantage was seen when comparing 3 frontline CDK4/6 inhibitor combinations in ...

Treatment with tafasitamab for relapsed/refractory DLBCL in the United States was supported by data from a retrospective ...

Long-term follow-up showed continued meaningful responses in patients with relapsed or refractory KMT2Ar acute leukemia who ...

An expanded analysis from the phase 3 CEPHEUS trial showed that daratumumab plus VRd improved MRD responses as well as ...

Cadonilimab plus platinum-based chemotherapy improved progression-free and overall survival in advanced cervical cancer ...

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast, according to 6-year data from the OlympiA trial.

By addressing these issues, we can ensure that all patients, regardless of their socioeconomic status, have the opportunity ...